Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continent Reinier Cornelis Anthonius van Linschoten , Elyke Visser, Christa Diana Niehot, C Janneke van der Woude , Jan Antonius Hazelzet, Desirée van Noord, Rachel Louise West.
Published May 2021, in Alimentary Pharmacology & Therapeutics. Summary Background: Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health
Inflammatory Bowel Disease in Maldives; A Single Center Clinical Experience
Published Jun 2021, in Birat Journal of Health Sciences. Abstract Introduction: Inflammatory bowel disease (IBD), once considered disease of west is also increasingly diagnosed in Asia in recent years. As there are already studies about IBD in Southeast Asia like India, Srilanka, it would be more informative to study the disease in Maldives as being closer to India and Srilanka. This is p
Diet and nutrition in the management of inflammatory bowel disease Sahu P, Kedia S, Ahuja V, Tandon RK.
Published Jun 2021, in the Indian journal of gastroenterology. Abstract The role of diet and its manipulation in the management of inflammatory bowel disease (IBD) is gradually acquiring central stage. Certain dietary factors have been identified as putative triggers in IBD as some other factors are found to be protective. The dietary manipulation as part of comprehensive I
Real-world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease. Vuyyuru SK, Kante B, Kumar P, Sahu P, Kedia S, Ranjan MK, Sharma R, Panwar R, Makharia G, Ahuja V Published Jun 2021, in the Scientific Reports. Abstract Crohn's disease (CD) is often complicated by strictures and associated with increased risk for surgery. Inflammatory strictures respond to medical therapy, and anti-tumor necrosis factor (TNF) th
Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome
Bolte LA, Vich Vila A, Imhann F, Collij V, Gacesa R, Peters V, Wijmenga C, Kurilshikov A, Campmans-Kuijpers MJE, Fu J, Dijkstra G, Zhernakova A, Weersma RK
Published Jul 2021, in the Gut. Abstract Objective: The microbiome directly affects the balance of pro-inflammatory and anti-inflammatory responses in the gut. As microbes thrive on dietary substrates, the q
Vaccinations in patients with inflammatory bowel disease
Macaluso FS, Liguori G, Galli M.
Published Jun 2021, in the Digestive and liver disease. Abstract Treatment of inflammatory bowel disease (IBD) frequently requires administration of immunosuppressive therapies, which increases susceptibility to a number of infectious pathogens. However, many infections can be prevented by correct and appropriate utilization of vaccinations. While several guidelines have been published o
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease Sinh P, Cross R. Published Jun 2021, in the Inflammatory bowel diseases. Abstract There is increased risk of cardiovascular disease in patients with chronic inflammatory disorders such as rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Studies have shown association between cardiovascular disease (eg, myocardial infarction, heart failur
Understanding attitudes, concerns, and health behaviors of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. Goodsall TM, Han S, Bryant RV. Published Jun 2021, in the Journal of gastroenterology and hepatology. Abstract Background and aim: The coronavirus disease 2019 (COVID-19) pandemic has led to a rapid shift in care delivery models for patients with inflammatory bowel disease (IBD); however, little is known about patient perceptions du
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. Published Jun 2021, in the Inflammatory bowel diseases. Abstract Background: Ustekinumab is currently approved globally in Crohn's disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis
Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents van Linschoten RCA, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL Published Jun 2021, in the Alimentary pharmacology & therapeutics. Abstract Background: Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide. Aim: To assess the cost of illness of IBD from
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN. Published Jul 2021, in the Clinical gastroenterology and hepatology. Abstract Background & aims: Patients with Crohn's disease (CD) or ulcerative colitis (UC) often receive combination